Brent Saunders

Brent Saunders is Chairman and CEO of Bausch + Lomb, in addition to serving as Chairman of both The Beauty Health Company and Roam. He is also a member of the Executive Board of Trustees of Mount Sinai Medical Center, a board advisor for Nextech and a director of ARS Pharmaceuticals, Cambrian BioPharma and Arena AI.

Prior to joining Bausch + Lomb in 2023, Mr. Saunders held a number of executive leadership positions and oversaw several major mergers and acquisitions. Notably, as President and CEO of Forest Laboratories, he led the company’s merger with Actavis, becoming CEO of the newly combined business. He then directed Actavis’ acquisition of Allergan, assuming the role of Chairman, President and CEO of Allergan until the company’s acquisition by AbbVie in 2020.

Earlier in his career, Mr. Saunders was a Partner at PricewaterhouseCoopers, President of Schering-Plough (where he oversaw the company’s acquisition of Organon BioSciences and subsequent merger with Merck) and President and CEO of Bausch + Lomb from 2010 to 2013.

Mr. Saunders has long been passionate about improving access to health care, especially mental health services. In 2021, the Child Mind Institute recognized his commitment to improving the lives of children with mental health and learning disorders by presenting him with the Child Advocacy Award. Mr. Saunders also supports The Michael J. Fox Foundation for Parkinson’s Research, as well as Community Hope, which provides mental health support to youths, veterans and their families. 

For updates and thought leadership from Mr. Saunders, follow him on LinkedIn, X, and Instagram.